| GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO) (NCT05109793) | Azafaros B.V. | 2022-02-22 |
| A Dose-escalation and Safety & Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease (NCT04669535) | Terence Flotte | 2021-01-15 |
| Registry Gangliosidoses (NCT04624789) | SphinCS Lyso Gemeinnutzige UG (Haftungsbeschrankt) | 2020-06-08 |
| Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 (NCT04470713) | Idorsia Pharmaceuticals Ltd. | 2019-07-31 |
| N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) (NCT03759665) | IntraBio Inc | 2019-06-07 |
| Synergistic Enteral Regimen for Treatment of the Gangliosidoses (NCT02030015) | University of Minnesota | 2015-12-22 |
| Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. (NCT01999257) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2014-07-01 |
| Longitudinal Study of Neurodegenerative Disorders (NCT03333200) | University of Pittsburgh | 2012-01-11 |
| Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders (NCT01372228) | Talaris Therapeutics Inc. | 2011-04-01 |
| Gene Therapy for Tay-Sachs Disease (NCT01869270) | University of Minnesota | 2010-12-01 |
| Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) (NCT01102686) | The Hospital for Sick Children | 2009-08-01 |
| HSCT for High Risk Inherited Inborn Errors (NCT00383448) | Masonic Cancer Center, University of Minnesota | 2006-09-01 |
| Diagnostic and Screening Study of Genetic Disorders (NCT00006057) | National Center for Research Resources (NCRR) | 1999-12-01 |
| Stem Cell Transplant for Inborn Errors of Metabolism (NCT00176904) | Masonic Cancer Center, University of Minnesota | 1995-01-01 |